Share Price, page-7728

indeed, and there's the possibility of treating traumatic brain injury as well. CSL's trading at a P/E multiple of 35.5 based on today's closing price of $248/share. Morning Star rates its fair value at $292 which gives it an even higher P/E multiplier. In contrast, BHP's trading at a P/E of 11.8 and NAB at 12.6. What gives the expectation that CSL's earnings are going to grow so much faster than BHP's or NAB's, and why shouldn't NEU be in that camp if NNZ2591 is proven commercially successful in a number of different treatments.